Primary cell culture

Globla Primary Cell Culture Industry's Vital Role in Advancing Precision Therapies and Regenerative Medicine Sparks Remarkable Growth - ResearchAndMarkets.com

Retrieved on: 
星期二, 九月 26, 2023
Health, Pharmaceutical, Tissue, Cell type, Primary cell culture, COVID-19, ATCC, USD, Regenerative medicine, Process control block, Patient, Organoid, Application, Cell, Drug discovery, Biology, Growth, Virus, Reagent, Wound healing, Vaccine

Primary cell culture, offering a closer emulation of human biology compared to traditional cell lines, has become indispensable for understanding disease mechanisms, advancing drug discovery, and facilitating therapeutic development.

Key Points: 
  • Primary cell culture, offering a closer emulation of human biology compared to traditional cell lines, has become indispensable for understanding disease mechanisms, advancing drug discovery, and facilitating therapeutic development.
  • Additionally, primary cell culture is playing a pivotal role in regenerative medicine, aiming to repair or replace damaged tissues and organs.
  • The growing interest and investment in regenerative medicine are propelling the growth of the primary cell culture market.
  • While the pandemic disrupted various sectors, it underscored the vital role of primary cell culture in comprehending viruses and developing treatments.

Primary Cells Market Research Report 2023: Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
星期三, 九月 13, 2023
Health, Genetics, Science, Stem Cells, Research, COPD, Corning Inc., Prevalence, Liver, Stemcell Technologies, Haematopoiesis, Biotechnology, Heart, Bone marrow, Cancer, Lung cancer, ATCC, Merck Group, DSM-IV codes, Cell, Human, Lung, USD, Cryopreservation, Stomach cancer, Incidence, Developed country, Investment, Melanoma, Immune system, Drug discovery, Growth, Transplant, Primary cell culture, Rest, ChromeOS, Fine chemical, Renewable energy, Vaccine, Video game, Pharmaceutical industry, Hepatocyte, Human musculoskeletal system

The "Global Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
  • On the basis of origin, the primary cells market is divided into animal and human primary cells.
  • In 2022, the human primary cells segment accounted for the largest share of the primary cells market.
  • Based on type, the primary cells market is segmented into hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells.

Sirnaomics Advances GalAhead(TM)-Based RNAi Therapeutics for Treatment of Complement-Related Diseases

Retrieved on: 
星期五, 八月 26, 2022
Schizophrenia, RNA interference, CEO, Technology, RNA, Múrna, Degenerative disease, Gene, IND, Primary cell culture, Board, Macular degeneration, Chemistry, Complement, Crohn's disease, Plasma, Angioedema, Immune system, Company, Therapy, Complement factor B, RNA transfection, Trial of the century, Alzheimer's disease, Pharmaceutical industry, Vaccine

and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ --Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases.

Key Points: 
  • and SUZHOU, China, Aug. 26, 2022 /PRNewswire/ --Sirnaomics Ltd.(the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the advancement of its GalAhead RNAi delivery platform for developing novel therapeutic products focused on complement-related diseases.
  • Sirnaomics' proprietary GalNAc-RNAi therapeutic platform, GalAhead, relies on unique RNA structures that allow the knockdown of single or multiple distinct mRNA targets, specifically two key technological components: mxRNA (miniaturized RNAi triggers) and muRNA (multi-unit RNAi triggers).
  • Complement-related diseases are amongst the important therapeutic areas Sirnaomics has selected for developing GalAhead-based treatments.
  • Sirnaomics has also developed a dual-targeting muRNA drug compound, STP247G, to inhibit both Complement Component C5 and Complement Factor B for the potential treatment of the complement-mediated immunologic disorders.

Global Cell Culture Market Report (2022 to 2031) - Featuring Thermo Fisher Scientific, Corning and Danaher Among Others - ResearchAndMarkets.com

Retrieved on: 
星期四, 三月 31, 2022
Biotechnology, Genetics, Health, Drug development, Cell, Risk, Regenerative medicine, Cancer Research Institute, Tissue engineering, 3D, Growth, Annual report, CRI, Environment, National Cancer Research Institute, Failure, Industry, Primary cell culture, Immortalised cell line, CGTC, Gene, Fine chemical

The cell culture market consists of sales of cell culture equipment and consumables for drug development and related services.

Key Points: 
  • The cell culture market consists of sales of cell culture equipment and consumables for drug development and related services.
  • The main types of cell culture are primary cell culture, secondary cell culture and cell line.
  • Hence, a surge in the demand for cell therapy aids in the growth of the cell culture market.
  • The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity.

Cell Culture Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com

Retrieved on: 
星期四, 十二月 9, 2021
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Cell, Primary cell culture, Merck, Environment, Risk, Gene, Company, Sartorius, Thermo Fisher Scientific, Cancer Research Institute, Growth, Sartorius AG, Tissue engineering, Failure, Annual report, Drug development, Danaher, Corning Inc., Mindful Scientific Inc., Industry, Immortalised cell line, Regenerative medicine, Becton, Dickinson and Company headquarters, COVID-19, National Cancer Research Institute, CRI, 3D, CGTC, Fine chemical, Pharmaceutical industry

The "Cell Culture Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cell Culture Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The cell culture market consists of sales of cell culture equipment and consumables for drug development and related services.
  • The cell culture market covered in this report is segmented by type into primary cell culture, secondary cell culture, cell line.
  • The development of products for 3D cell culture by the companies operating in the cell culture market is gaining significant popularity.